CD Bioparticles Launches Custom Latex Immunoturbidimetric Assay (LIA) Development Services to Accelerate IVD Innovation
Sep 22, 2026
CD Bioparticles launches end-to-end Custom Latex Immunoturbidimetric Assay development services for research applications.
New York, NY, United States, September 22, 2026 /MarketersMEDIA/ -- With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its diagnostic capabilities with the launch of its end-to-end Custom Latex Immunoturbidimetric Assay development services. These services offer full-spectrum assay customization ranging from particle conjugation to fully optimized kit assembly, and can help researchers and diagnostic developers to streamline IVD reagent manufacturing and clinical biomarker quantification.
The immunoturbidimetry method is an analytical technique combining liquid-phase precipitation reactions with optical instruments and automated analysis. However, due to issues relating to the size and quantity of antigen-antibody complexes, the immunoturbidimetry has low sensitivity and a narrow detection range. This has led to the development of the latex immunoturbidimetric assay (LIA). This technique uses latex microparticles that are coated with specific antibodies or antigens.
When these particles encounter the target analyte in a sample, they form specific aggregates through antigen-antibody interactions. The aggregation of these particles increases the scattering intensity or absorbance of the latex suspension. This increase is quantitatively correlated with the concentration of the target analyte in the sample. Turbidity measurements are performed using a biochemical analyser, and the entire analytical process takes only a few minutes. Compared to traditional immunoturbidimetric methods, this method offers significantly higher sensitivity, with detection limits as low as ng/mL or pg/mL.
CD Bioparticles has extensive experience in assay solutions and now offers custom services to help researchers and diagnostic product developers develop latex immunoturbidimetric assays. The company's service portfolio ranges from custom conjugation to the optimization of complete immunoturbidimetric assays. The company provides custom-made, carboxyl-functionalized polystyrene microspheres that are conjugated with antigens or antibodies and come in various sizes. CD Bioparticles also offers complete kits for the quantitative detection of a wide range of biomarkers. These products feature high sensitivity, short assay times and compatibility with automated biochemical analyzers.
CD Bioparticles offers customers carboxyl-modified polystyrene microparticles in a range of sizes (from 0.07 to 0.4 μm) that are suitable for developing latex immunoturbidimetric assay reagents. CD Bioparticles' standard products feature a moderate surface carboxyl density; products with higher or lower densities are also available upon request. Additionally, CD Bioparticles can customize the conjugation of antibodies and antigens to meet specific application requirements. Through optimization, the team can ensure high conjugation efficiency while maintaining the activity of both antibodies and antigens.
CD Bioparticles also offers reagent formulation development and optimization services to help customers improve reagent stability, optimize reaction conditions and enhance detection sensitivity. The company offers performance validation services to verify key performance indicators, including linearity, sensitivity, specificity and precision, ensuring stability across different batches and under various operating conditions.
For more information about CD Bioparticles' Custom Latex Immunoturbidimetric Assay development services or to submit a project inquiry, please visit https://www.cd-bioparticles.com/services/latex-immunoturbidimetric-assay-development.html.
About CD Bioparticles
CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.
Contact Info:
Name: Richard J. Gray
Email: Send Email
Organization: CD Bioparticles
Website: https://www.cd-bioparticles.com/
Release ID: 89204007
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
More News
'We screwed up': Doordash admits underpaying New York workers
The food delivery giant will pay a $131.5m settlement following a city probe into wage violations.
Global Oil Price Drops Below $100 a Barrel
Investors anticipated that a damaged Saudi Arabian pipeline may be close to reopening, allowing more oil from the region to reach world markets.
Trump Is Back on TV, Briefly, as Many Networks Carry His U.N. Speech Live
A suspension of pool coverage remains in effect. But the in-house United Nations broadcaster provided a feed of the president’s remarks.
Sir Jim Ratcliffe suspends production at key UK plants blaming high gas prices
Ineos said natural gas in the UK is twelve times more expensive than in the US.
How Unions Are Confronting A.I. Threats in the Workplace
The machinists union shows how workers are negotiating for a say in the ways artificial intelligence is used in their workplaces.
What Is the White House Press Pool, and Why Did It Suspend TV Coverage of Trump?
By barring CNN, the White House has thrown a staple of TV news coverage into disarray.
CNN’s Future Will Include an Editorial Oversight Board
The looming ownership of the network by David Ellison has caused anxiety in its newsroom for months.
What’s Next for Paramount
Hollywood watchers believe the studio prevailed over states seeking to block its deal for Warner Bros. Discovery. It’s now free to reshape the media industry.
China’s Continued Control of Rare Earths Looms Over Trump-Xi Meeting
Manufacturers are struggling with constrained supplies as U.S. and Chinese officials negotiate over export restrictions with consequences for global industry.
Paramount settles lawsuit with US states, clearing way for $110bn merger with Warner Bros
The deal includes an agreement to produce 30 films a year, or Paramount will be forced to sell off parts of its company.
Are vet bills about to get cheaper?
Written prescription fees from vets will be capped at £21 as part of a raft of changes that practices will be legally required to bring in over the coming months.
Spain battles climate change on several fronts
A summer of wildfires and heatwaves underlines the threats to the country's economy.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.